Document is current
Any future updates will be listed below
-
Authors
Laxer, Kenneth D.
Elder, Christopher J.
Di Gennaro, Giancarlo
Ferrari, Louis
Krauss, Gregory L.
Pellinen, Jacob
Rosenfeld, William E.
Villanueva, Vicente
-
Funding
Funding for this research was provided by:
SK Life Science
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 23 July 2024
First Online: 18 August 2024
Declarations
:
: Kenneth D. Laxer: Consultant/advisor: SK Life Science, Inc.; Speaker: SK Life Science, Inc.; Research support: SK Life Science, Inc.; Xenon. Christopher J. Elder: Speaker, SK Life Science, Inc. Giancarlo Di Gennaro: Consultant/advisor: Angelini Pharma, UCB Pharma; Speaker: Angelini Pharma, Eisai, LivaNova, Lusofarmaco, Neuraxpharm. Louis Ferrari: Employee: SK Life Science, Inc. Gregory L. Krauss: Angelini, SK Life Science, Inc.; Research support: Cerevel, Neuroelectrics, UCB Pharma. Jacob Pellinen: Consultant/advisor: SK Life Science, Inc. William E. Rosenfeld: Consultant/advisor: SK Life Science, Inc.; Speaker: SK Life Science, Inc.; Research support: SK Life Science, Inc., UCB Pharma. Vicente Villanueva: Consultant/advisor: Angelini, BIAL, Eisai, Esteve, GlaxoSmithKline, Jazz, Novartis, Sandoz, Takeda, UCB Pharma, Xenon; Speaker: Angelini, BIAL, Cevomed, Eisai, Esteve, Jazz, Newbridge, Paladin, UCB Pharma; Research support: Angelini, BIAL, Eisai, Jazz, UCB Pharma.
: This work is based on previously conducted studies and the clinical expertise of the authors in treating patients with epilepsy. All participants/panelists were authors of this study. No new clinical studies were performed by the authors. No patient-specific efficacy or safety data were reported; therefore, institutional review board (IRB)/ethics approval was not required for the expert panel recommendations. Any previously conducted clinical studies were all IRB-approved.
